Health Canada has approved Neffy, the first needle-free epinephrine nasal spray designed to treat severe allergic reactions, marking a significant shift in how anaphylaxis is managed in emergency settings. The approval provides a non-invasive alternative to the traditional auto-injectors that have been the gold standard for decades.
Distributed in Canada by ALK Canada, the 2 mg dose of the nasal spray is approved for adults and children weighing at least 30 kg (approximately 66 pounds). The company indicates that the treatment could be commercially available as early as this summer, offering a new lifeline to those living with life-threatening allergies.
For many patients, the primary barrier to the immediate administration of epinephrine during an allergic crisis is the fear of needles or the complexity of using an auto-injector under extreme stress. By moving the delivery system from the muscle to the nasal mucosa, Neffy aims to reduce the psychological barrier to treatment and potentially speed up the response time during a medical emergency.
Moving Beyond the Needle
Until now, the only emergency options available to Canadians facing anaphylaxis were epinephrine auto-injectors, most commonly known by the brand name EpiPen. These devices are pre-filled, single-use injectors that deliver a concentrated dose of epinephrine into the thigh muscle via a needle.
Epinephrine works by rapidly constricting blood vessels to increase blood pressure and relaxing the muscles in the airways to allow breathing to resume. While highly effective, the intramuscular route requires a specific technique—swinging and firmly pressing the device against the outer thigh—which can be daunting for children or caregivers in the midst of a panic-inducing reaction.
The nasal spray utilizes a different delivery mechanism, absorbing the medication through the lining of the nose. This method eliminates the need for a needle and the associated risk of injection-site errors, such as accidental discharge into a finger or failure to penetrate clothing.
Comparing Delivery Methods
The introduction of a nasal alternative allows for a comparison of the two primary emergency delivery systems currently available or entering the market.
| Feature | Auto-Injectors (e.g., EpiPen) | Nasal Spray (Neffy) |
|---|---|---|
| Administration Route | Intramuscular (Thigh) | Intranasal (Nose) |
| Needle Required | Yes | No |
| Canadian Approval | Established | Approved (2 mg dose) |
| Weight Requirement | Varies by dose | $ge$ 30 kg (for 2 mg) |
The Gap in Pediatric Care
While the approval is a victory for many, there remains a gap in the available dosages for the youngest patients. In the United States, where the U.S. Food and Drug Administration (FDA) approved Neffy in the summer of 2024, a 1 mg dose is available for children weighing between 15 and 30 kg.
Currently, this lower dose has not been approved by Health Canada. Children under 30 kg in Canada will continue to rely on pediatric auto-injectors for emergency treatment. For clinicians and parents, In other words that the transition to needle-free care will be phased, depending on the patient’s weight and the specific regulatory approvals in place.
Food Allergy Canada has welcomed the 2 mg approval, describing the authorization as an important advancement that provides Canadians with more choices in managing severe allergies.
Clinical Implications and Patient Safety
From a medical perspective, the effectiveness of a nasal spray depends on the rate of absorption. Epinephrine must reach the bloodstream quickly to reverse the systemic collapse associated with anaphylaxis. The approval by Health Canada suggests that the nasal delivery of the 2 mg dose provides a therapeutic level of epinephrine sufficient to stabilize patients in an emergency.
But, medical professionals emphasize that a nasal spray is not a replacement for professional medical care. Anaphylaxis is a medical emergency; regardless of whether a patient uses an auto-injector or a nasal spray, immediate transport to an emergency department is required. What we have is because epinephrine is a short-acting medication, and “biphasic reactions”—where symptoms return after the initial dose wears off—can occur.
Patients transitioning to Neffy will still need proper training. While the device is simpler than a needle, ensuring the spray is administered correctly into the nasal cavity is essential for maximum absorption.
For those who have historically avoided carrying their epinephrine due to needle phobia, this approval may increase the likelihood that they have the medication on hand when We see most needed. In the world of allergy management, the best medication is the one the patient is actually willing to use.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next milestone for the rollout of Neffy in Canada will be its official commercial launch, expected later this summer, at which point pricing and provincial insurance coverage details will grow available.
Do you or your family manage severe allergies? Share your thoughts on this new needle-free option in the comments below.
